Late-Breaking Ph 2b RCT of TAK-279, oral TYK2 Inhib, in Active PsA. ACR20 in 53-54% (30 mg qd) vs 29.2% PBO at wk 12 (p
Tweet Content
Late-Breaking Ph 2b RCT of TAK-279, oral TYK2 Inhib, in Active PsA. ACR20 in 53-54% (30 mg qd) vs 29.2% PBO at wk 12 (p = 0.002). Abst #L12 presented on Tuesday. #ACR23
Show on Archive Page
On
Display in Search Results
On
PDQ
Off